Access Robust Datasets, Successfully Harness AI, & Streamline Integrated Evidence Planning to Identify Commercial Opportunities, Drive Efficiency, Support Regulatory & HTA Decision-Making, & Accelerate Speed to Market
Real-world evidence has reached an inflection point. As AI, advanced analytics and the evolving European Health Data Space reshape evidence generation, RWE is becoming a strategic driver of drug development, regulatory strategy and market access. The challenge now is turning increasingly complex datasets into robust, actionable evidence.
The 4th IMPACCT Real World Evidence Summit Europe brings together senior RWE, Evidence Generation, Medical Affairs and Market Access leaders to explore how to build regulatory-grade datasets, govern AI responsibly, navigate fragmented European data landscapes and embed RWE earlier through integrated evidence planning. Hear practical case studies from Pfizer, AstraZeneca, Novartis, Bayer, Novo Nordisk, UCB, Gilead, Boehringer Ingelheim, Takeda and more.
Beyond the presentations, interactive roundtables, debates, problem-solving clinics and dedicated networking create opportunities to exchange honest insights, tackle shared challenges and build lasting relationships with peers.
2027 Speakers
Attending Companies Include